Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takeshi Okamoto has a total of 187 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of Reintervention Outcomes After Endoscopic Ultrasound-Guided Hepaticogastrostomy According to the Type of Initial Stent

    by Yukari Suzuki, Takashi Sasaki, Tsuyoshi Takeda, Masashi Miura, Masanori Nagasawa, Toyokazu Saito, Yuri Maegawa, Takafumi Mie, Takeshi Okamoto, Masato Ozaka, et al.

    Background/Objectives: The impact of initial stent type on endoscopic reintervention after endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) remains unclear. Methods: We retrospectively evaluated patients with malignant biliary obstruction who developed recurrent biliary obstruction (RBO) after EUS-HGS and underwent reintervention through the endosonographically created route (ESCR). Outcomes were compared according to initial stent type (plastic stent [PS] or self-expandable metallic stent [SEMS]). The association between initial stent type and time to RBO (TRBO) after definitive biliary drainage was assessed using Cox regression and Fine–Gray regression. Results: Of 170 patients who underwent EUS-HGS, 69 were included (PS, n = 23; SEMS, n = 46). The initial reintervention procedure was technically successful in 100% and 95.7% of patients, respectively (p = 0.55). Definitive biliary drainage was technically successful in all 69 patients, while clinical success was achieved in 62 (89.9%). No procedure-related adverse events were observed. Among patients with clinical success, median TRBO was 160 and 140 days in the PS and SEMS groups, respectively. Initial SEMS placement was not significantly associated with TRBO (adjusted hazard ratio, 1.32; 95% confidence interval [CI], 0.55–3.13) or the cumulative incidence of RBO (adjusted subdistribution hazard ratio, 1.67; 95% CI, 0.70–3.97). Conclusions: Endoscopic reintervention through the ESCR was technically feasible after both initial PS and SEMS placement. Initial stent type was not significantly associated with subsequent RBO, although the findings should be interpreted cautiously because of potential temporal confounding and the limited sample size.

  • Open Access

    Comparison of Two Partially Covered Metal Stents for Endoscopic Ultrasound‐guided Hepaticogastrostomy: A Multi‐Center Retrospective Study

    by Masahiro Yamamura, Hirotoshi Ishiwatari, Saburo Matsubara, Takeshi Okamoto, Michihiro Ono, Toshinori Okuda, Etsuji Ishida, Kohichi Takada, Kazuma Ishikawa, Naoki Sasahira, et al.

    Objectives: Endoscopic ultrasound‐guided hepaticogastrostomy (EUS‐HGS) is an alternative biliary drainage method after failed endoscopic retrograde cholangiopancreatography. Nevertheless, it is associated with adverse events (AEs), including peritonitis and stent migration. The influence of metallic stent (MS) design characteristics, including axial force (AF), on the safety and efficacy of EUS‐HGS remains unclear. Methods: This multicenter retrospective study included patients with unresectable malignant biliary obstruction who underwent EUS‐HGS using either a high‐AF MS (Niti‐S biliary S‐type) or a low‐AF MS (EGIS biliary) between January 2019 and December 2022. Propensity score matching was performed in a 1:2 ratio. Outcomes included clinical success, early and late non‐recurrent biliary obstruction (non‐RBO) AEs, RBO, time to RBO (TRBO), and overall survival (OS). Results: After matching, 27 patients in the high‐AF group and 54 in the low‐AF group were analyzed. Clinical success, RBO rate, TRBO, OS, and late non‐RBO AE rates were similar between groups. However, early non‐RBO AEs were more frequent in the high‐AF group (37% vs. 13%, p = 0.02). Conclusions: Of the two partially covered MSs evaluated, the EGIS biliary stent demonstrated fewer early non‐RBO AEs after EUS‐HGS.

  • Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy

    by Tsuyoshi Takeda, Masato Ozaka, Takashi Sasaki, Yosuke Inoue, Tatsuki Hirai, Takafumi Mie, Takaaki Furukawa, Takeshi Okamoto, Yu Takahashi, Naoki Sasahira

    Background: Neoadjuvant chemotherapy (NAC) with gemcitabine and S‐1 (GS) is the standard regimen for resectable pancreatic cancer (PC) in Japan. However, its efficacy in elderly patients and those with impaired renal function remains unclear. Methods: We retrospectively analyzed patients with resectable PC who received NAC GS. Patients were classified as elderly (≥ 75 years) or non‐elderly (< 75 years). The primary endpoint was relative dose intensity (RDI) of NAC. Secondary endpoints included adverse events (AEs), perioperative outcomes, RDI of adjuvant chemotherapy (AC), recurrence‐free survival (RFS), and overall survival (OS). Results: A total of 185 patients were included (non‐elderly: 148, elderly: 37). Median creatinine clearance (CCr) was lower in elderly patients (64.2 vs. 84.5 mL/min, p < 0.001). Mean RDI of GS was significantly lower in elderly patients and those with CCr < 50 mL/min, particularly when both factors coexisted. Severe hematologic AEs were more frequent in these groups, though perioperative outcomes were similar. While initiation of AC was delayed and RDI of adjuvant S‐1 was lower in elderly patients, RFS and OS did not significantly differ between groups. Conclusions: NAC GS appears feasible in elderly patients with resectable PC, though caution is needed in those with impaired renal function.

  • Gastrointestinal Bleeding after Particle Radiotherapy for Pancreatic Cancer

    by Takeshi Okamoto, Takafumi Mie, Tsuyoshi Takeda, Keito Suzuki, Yoichiro Sato, Tatsuki Hirai, Yuri Maegawa, Jun Hamada, Takaaki Furukawa, Takashi Sasaki, et al.

    Introduction: Particle radiotherapy (PRT) is a new option for the treatment of unresectable pancreatic cancer (PC). While gastrointestinal bleeding (GIB) is a feared adverse event, real-world evidence in this setting is limited. Methods: We conducted a single-center retrospective study to evaluate the frequency and outcomes of GIB and to elucidate the risk factors for GIB after PRT for PC. Results: Thirty-four patients were included. Twenty-nine received PRT to the pancreatic primary, while five received PRT for metastases. Concurrent chemotherapy was given to 26 patients (76%). Eleven patients (32%) experienced acute GIB symptoms after PRT. Median time from PRT to GIB was 13.2 months. Endoscopic signs of hemorrhage were observed in 8 patients (24%), and endoscopic hemostasis was performed in six (18%). Three cases presented with ruptured pseudoaneurysms, of which two were treated with transarterial embolization. Hemostasis was ultimately achieved in all cases, and no deaths occurred directly as a result of GIB. However, overall survival after GIB was short (median: 1.9 months). Median overall survival after PRT tended to be longer in bleeders than in non-bleeders (26.8 vs. 22.7 months, p = 0.03). Concurrent chemotherapy was associated with a lower risk of GIB in univariate analysis (p = 0.05). Conclusion: GIB after PRT may not be as rare as previously believed, particularly in the terminal stages of PC.

  • Progressive Sarcopenia as a Prognostic Marker in the Era of Immunotherapy

    by Takeshi Okamoto, Takashi Sasaki, Masato Ozaka, Naoki Sasahira

  • Clinical predictors of KRAS mutation detection in liquid biopsies for pancreatic ductal adenocarcinoma

    by Takaaki Furukawa, Ippei Fukada, Naomi Hayashi, Takeshi Okamoto, Yoichiro Sato, Yuri Maegawa, Tatsuki Hirai, Takafumi Mie, Tsuyoshi Takeda, Takashi Sasaki, et al.


  • Bone loss, osteoporosis, and fractures in patients with resected pancreatic head cancer

    by Tsuyoshi Takeda, Takashi Sasaki, Yosuke Inoue, Takeshi Okamoto, Tatsuki Hirai, Takafumi Mie, Takaaki Furukawa, Yukari Suzuki, Masato Ozaka, Yu Takahashi, et al.


  • Pathological complete response following addition of durvalumab to gemcitabine and cisplatin therapy for intrahepatic cholangiocarcinoma with Lynch syndrome-associated mismatch repair deficiency

    by Koshiro Fukuda, Akiyoshi Kasuga, Yasuyuki Shigematsu, Kenichiro Kato, Hiromichi Ito, Arisa Ueki, Takeshi Okamoto, Masato Ozaka, Yu Takahashi, Naoki Sasahira

    A 64-year-old man with a history of surgery for rectal cancer and colon cancer was referred for a hepatic mass identified on computed tomography (CT). He was diagnosed with unresectable intrahepatic cholangiocarcinoma (ICC) with perihilar and para-aortic lymph node metastases. After 4 cycles of gemcitabine and cisplatin combination therapy (GC therapy), follow-up CT showed slight enlargement of the primary tumor and a slight increase in carbohydrate antigen (CA) 19–9. Genetic testing was performed during GC therapy based on the strong family history of cancer. Germline pathogenic variant in MLH1 was identified, leading to the diagnosis of Lynch syndrome (LS) with mismatch repair deficiency (dMMR: loss of MLH1/PMS2). Durvalumab was added to GC therapy following regulatory approval in Japan. A significant reduction in tumor size and CA19-9 was observed after only two cycles of GC and durvalumab therapy. Continuous improvement was observed, and conversion surgery involving liver resection, partial inferior vena cava resection, and perihilar and para-aortic lymph nodes dissection was performed with curative intent. No malignant cells were found in any of the resected specimens, consistent with pathological complete response.


  • Liver Oligometastasis in Biliary Tract Cancer and Impact on Survival Outcomes

    by Takeshi Okamoto, Tsuyoshi Takeda, Takashi Sasaki, Yosuke Inoue, Takafumi Mie, Tatsuki Hirai, Takahiro Ishitsuka, Manabu Yamada, Hiroki Nakagawa, Takaaki Furukawa, et al.

    Purpose Outcomes of unresectable biliary tract cancer (BTC) with varying extents of liver involvement remain unclear. We evaluated characteristics and outcomes of BTC patients with liver metastases who underwent chemotherapy. Methods We retrospectively reviewed consecutive BTC patients with synchronous or metachronous intrahepatic metastases who started first-line chemotherapy at our institution between January 2016 and December 2021. Results Ninety-six patients were included, of which 57 only had liver metastases and 39 had multiorgan involvement. The liver only group had longer median overall survival (OS) (11.8 vs. 7.4 months, P = 0.006) and median progression-free survival (PFS) (4.1 vs. 2.7 months, P = 0.035) than the multiorgan group. Patients with oligometastases (defined as no more than three liver metastases) achieved longer OS than those with polymetastases (four or more liver metastases) in the entire cohort. Within the liver only group, there were no significant differences in OS or PFS between the oligometastasis and polymetastasis groups. Patients who underwent subsequent surgery had significantly longer median OS than those who did not (44.4 vs. 7.7 months, P < 0.001). Age ≥ 75 years, liver-only metastasis, modified Glasgow prognostic score ≥ 1 carcinoembryonic antigen ≥ 5 μg/L, and subsequent surgery were independent predictors of OS. Liver oligometastasis was only a significant predictor of longer OS in univariate Cox analysis. Conclusions Outcomes in BTC patients with metastases limited to the liver, particularly those with oligometastasis, were more favorable than those with multiorgan metastases. Selected cases, generally with liver oligometastases, may achieve prolonged OS through subsequent surgery.


  • Open Access

    Outcomes of partially covered self-expandable metal stents with different uncovered lengths in endoscopic ultrasound-guided hepaticogastrostomy: a Japanese retrospective study

    by Takeshi Okamoto, Takashi Sasaki, Tsuyoshi Takeda, Tatsuki Hirai, Takahiro Ishitsuka, Manabu Yamada, Hiroki Nakagawa, Takafumi Mie, Takaaki Furukawa, Akiyoshi Kasuga, et al.

    Background/Aims: The optimal length of the uncovered portion of partially covered self-expandable metal stents (PCSEMSs) used in endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) remains unclear. This study investigated the safety and efficacy of PCSEMSs with different uncovered lengths, with a focus on stent migration and time to recurrent biliary obstruction (RBO).Methods: Outcomes of patients undergoing EUS-HGS using PCSEMSs with 5-mm and 20-mm uncovered portions at our institution from January 2016 to December 2021 were compared.Results: Sixty-two patients underwent EUS-HGS using PCSEMS (5/20-mm uncovered portions: 32/30). Stent migration occurred only in the 5-mm group. There were no differences in RBO rates (28.1% vs. 40.0%) or median time to RBO (6.8 vs. 7.1 months) between the two groups. Median overall survival (OS) was longer in the 20-mm group (3.1 vs. 4.9 months, p=0.037) due to the higher number of patients that resumed chemotherapy after EUS-HGS (56.7% vs. 28.1%, p=0.029). Good performance status, absence of hepatic metastases, and chemotherapy after EUS-HGS were independent predictors of longer OS.Conclusions: No migration was observed in patients treated with PCSEMS with 20-mm uncovered portions. Patients treated with PCSEMS with 20-mm uncovered portions performed at least as well as those treated with 5-mm uncovered portions in all material respects.